ORIGINAL ARTICLE |
|
Year : 2019 | Volume
: 32
| Issue : 4 | Page : 1506-1511 |
|
Soluble suppression of tumorigenisity 2 as an indicator of severity of heart failure in children with congenital acyanotic heart diseases
Rania S Elzayat1, Ahmed A Khattab1, Mohammed S Rizk2, Rabab M Shaban3
1 Department of Pediatrics, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt 2 Department of Medical Biochemistry and Molecular Biology, Faculty of Medicine, Menoufia University, Shebin El Kom, Egypt 3 Department of Pediatric, Pediatrics at Ministry of Health, Shebin El Kom, Egypt
Correspondence Address:
Rabab M Shaban Tala, Menoufia Egypt
Source of Support: None, Conflict of Interest: None | Check |
DOI: 10.4103/mmj.mmj_154_19
|
|
Objective
We aimed to evaluate the role of soluble suppression of tumorigenisity 2 (sST2) as an indicator of severity of heart failure (HF) in children with congenital acyanotic heart diseases.
Background
HF in congenital heart diseases (CHD) is a serious problem encountered in early infancy or later. It is a significant cause of morbidity and mortality in children with CHD. SST2 is currently gaining interest as a biomarker in cardiac disease.
Patients and methods
A prospective comparative study was conducted on 60 children having CHD with left-to-right shunt from the Pediatric Department of Menoufia University Hospitals between August 2017 and August 2018 and were divided into two groups: group 1: 30 children with manifestation of HF. Group 2: 30 children without manifestation of HF. In addition, 25 age-matched and sex-matched healthy children were set as a control group. All children were subjected to a full clinical history and examination. Serum level of sST2 were determined.
Results
Level of sST2 was 82.2 ± 22.3 and 25.63 ± 19.33 ng/ml in patients with and without HF, respectively. SST2 was significantly higher in patients who developed HF than in those without HF (P < 0.001). SST2 was significantly elevated with increased severity of HF (P < 0.001), wherein it was 25.63 ± 19.3, 55.5 ± 2.6, 86.1 ± 7.7, and 109.9 ± 6.4 ng/ml in patients with ROSS class I, II, III, and IV, respectively.
Conclusion
SST2 is a promising novel cardiac biomarker that could reflect the severity of HF.
|
|
|
|
[FULL TEXT] [PDF]* |
|
|
|